The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent by ...

The CEO of Swiss pharmaceuticals behemoth Roche (OTCQX:RHHBY) said he believes antitrust regulators should not allow Novo ...

The groups behind the letter alleged that Novo Nordisk’s plant purchases could hinder not only the Danish drugmaker’s chief ...

Roche CEO Urges FTC to Block Novo Nordisks Acquisition of Catalent Roches CEO, Thomas Schinecker, has called on authorities ...

Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised ...

Jefferies analyst Peter Welford noted that Roche’s pharma group came just slightly ahead of consensus expectations, driven by ...

Yale spinout Modifi agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to market ...

U.S. consumer groups and labor unions have called on the Federal Trade Commission to block Novo Holdings from acquiring ...

A Roche spokesperson declined ... that Novo Holdings plans to sell on to Novo Nordisk. Sarepta does not anticipate any impact from the Catalent acquisition, spokesperson Tracy Sorrentino said ...

Consumer groups, labor unions, and Senator Elizabeth Warren have urged the FTC to block Novo Holdings from acquiring Catalent. Concerns center on competition in weight loss drugs and gene therapies.

FRANKFURT (Reuters) - The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug ...

the controlling shareholder of Novo Nordisk, from acquiring contract drug manufacturer Catalent, saying the deal threatens competition in weight loss drugs and cutting-edge gene therapies.